A Multicenter, Open-label, Follow-up Study to Assess the Long-term Use of Lacosamide (Flexible Dose From 200 to 600 mg/Day) Used as Monotherapy in Subjects Who Completed SP0994 and Received Lacosamide Monotherapy Treatment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Lacosamide (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB
- 20 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 26 Oct 2015 New trial record